Start with the obvious. Endobronchial ultrasonography (EBUS) has revolutionized the diagnosis and staging of lung cancer and other thoracic pathologic conditions. The literature overflows with support of its benefits, and the paper by Gildea and Nicolacakis in this issue of CHEST alludes to the nearly 1,000 papers published previously. I would go so far as to state that EBUS has had a more profound and practical impact on the care of patients with thoracic cancer and those with benign conditions than all the more recent genetic testing, targeted therapy, high-technology robotics, and other media-worthy treatments of the past 5 years. By properly staging, avoiding unnecessary procedures and risk of complications, directing the patient to the most effective therapy quickly and efficiently, outcomes and quality of life cannot help but be positively impacted.